周剂量多西紫杉醇和顺铂同步放化疗治疗42例Ⅲ期非小细胞肺癌患者的临床观察  

Clinical study on weekly docetaxel and cisplatin concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer

作　　者：付相建[1] 杨光华[1] 薛跃辉[1] 付尚志[1] 

机构地区：[1]解放军第三二四医院肿瘤科,重庆400020

出　　处：《重庆医学》2010年第21期2926-2928,共3页Chongqing medicine

摘　　要：目的评估周剂量多西紫杉醇和顺铂同步放化疗治疗Ⅲ期非小细胞肺癌的疗效及毒副作用。方法 42例不能手术的Ⅲ期非小细胞肺癌患者(Ⅲa期18例,Ⅲb期24例),接受多西紫杉醇20 mg/m2、顺铂25 mg/m2每周给药1次化疗和总量60Gy的同步放疗(2Gy/次,5次/周)。结果近期有效率为76.2%,平均随访22个月,中位生存期为17.2个月,中位局部无进展生存时间为13.5个月,1、2、3年的生存率分别为78.6%、35.7%、19.5%。放化疗的毒性反应主要是骨髓抑制,放射性食管炎和胃肠道反应,经对症处理能完成治疗,无治疗相关死亡。结论周剂量多西紫杉醇和顺铂同步放化疗治疗Ⅲ期非小细胞肺癌具有较好的近期与远期疗效,不良反应可耐受。Objective To evaluate the clinical curative effect and side effect of weekly docetaxel and cisplatin concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer.Methods Forty-two cases with non-operated stage Ⅲ non-small cell lung cancer（Ⅲa 18,Ⅲb 24）received weekly docetaxel（20 mg/m2） and cisplatin（25mg/m2） along with concurrent radiotherapy at a total dose of 60Gy（2Gy/ fraction and 5 fractions per week）.Results The effective rate was 76.2% after concurrent chemoradiotherapy.The average follow up time was 22 months.The median survival time was 17.2 months and the median local progression-freely survival time was 13.5 months.The 1-,2-and 3-year survival rate was 78.6%,35.7% and 19.5%,respectively.The major complications were hematopoietic depression,radiation esophagitis and nausea or vomiting,but the toxicities were manageable without treatment-related mortality.Conclusion Weekly docetaxel and cisplatin concurrent chemoradiotherapy is an effective and tolerable treatment method for stage Ⅲ non-small cell lung cancer.

关 键 词：非小细胞肺癌 多西紫杉醇 顺铂 同步放化疗 

分 类 号：R734.2[医药卫生—肿瘤]